However, due to the heterogeneity of HNSCC tumors, PSMG2 might be a good marker for the activity of proteasome inhibitors only in a subset of tumors, since only one cell line is more sensitive to proteasome inhibitors. This evidence concerns the gene PSMG2 and head and neck squamous cell carcinoma.